drugset / Trial / NCT02051335
Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether scopolamine-induced cognitive impairment is attenuated by the administration of roflumilast in combination with donepezil.
Timeline
- Start
- 2014-01
- Primary completion
- 2014-05
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donepezil | Small molecule | 10 mg | Oral |
| Subject | Roflumilast | Small molecule | — | Oral |
| Background | Scopolamine | Unknown | 0.5 mg | Subcutaneous |